Nitrase Therapeutics is a clinic-ready biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a new class of enzymes discovered in-house with promise against a broad variety of diseases. Our breakthrough discovery of the enzymatic nature of protein nitration by nitrases, as well as our understanding of their exquisitely selective and specific mechanism of action, enables the advancement of a novel pipeline of therapeutics.

Our lead program is NDC-0524, a first-in-class antibody designed to selectively target the pathogenic form of alpha-synuclein associated with Parkinson’s disease. Supported by strong preclinical efficacy and safety, NDC-0524 is ready to advance into a Phase 1/2a clinical study and has the potential to become a transformative disease-modifying therapy for Parkinson’s disease. Additionally, we are developing a small-molecule inhibitor of Synuclein Nitrase, the enzyme responsible for generating the pathogenic form of alpha-synuclein, which would be complementary to antibody-based approaches.

As pioneers in the field, we are in a unique position to discover and develop additional novel medicines for diseases in which nitrases and nitro-substrates play a role, including other neurodegenerative diseases, cancer, fibrotic diseases, respiratory diseases, and autoimmune diseases.

Nitrase Therapeutics (under the former name Nitrome Biosciences) has been widely recognized and has won multiple awards, including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).